Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 8, 2007, Pages 1220-1225

  Kim, Ji H ^a   Yu, Sang K ^b   Seo, Yeon S ^a   Yim, Hyung J ^a   Yeon, Jong E ^a   Park, Jong J ^a   Kim, Jae S ^a   Bak, Young T ^a   Lee, Chang H ^b   Byun, Kwan S ^a  

^a Korea University College of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Hepatitis B virus DNA; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYBRIDIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SERODIAGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS DETECTION;

EID: 34547652163     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04921.x     Document Type: Article

References (26)

1. Perrillo RP. Treatment of chronic hepatitis B with interferon: experience in western countries. Semin. Liver Dis. 1989 9 : 240 8.
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: meta-analysis. Ann. Intern. Med. 1993 119 : 312 23.
3. Lau DT, Everhart J, Kleiner DE et al. Long term follow-up of chronic hepatitis B patients with interferon alfa. Gastroenterology 1997 113 : 1660 7.
4. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow up of chronic hepatitis B patients with interferon alfa. Gastroenterology 1993 105 : 1833 8.
5. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+) and (-) -2,3-dideoxy-3-thiocytidine as anti-hepatitis B virus agents. J. Biol. Chem. 1992 267 : 22414 20.
6. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995 333 : 1657 61.
7. Lai CL, Chien RN, Leung NWY et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998 339 : 61 8.
8. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998 27 : 1711 16.
9. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetant chronic hepatitis B. Incidence and patterns. J. Hepatol. 1997 26 : 1393 5.
10. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000 119 : 172 80.
11. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis b e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000 32 : 803 6.
12. Byun KS, Kwon OS, Kim JH et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J. Gastroenterol. Hepatol. 2005 20 : 1838 42.
13. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose ranging study. Gastroenterology 1997 113 : 1258 63.
14. Hong SP, Kim NK, Hwang SG et al. Detection of hepatitis B virus variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 2004 40 : 837 44.
15. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996 111 : 1018 22.
16. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 32 : 828 34.
17. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in United States. N. Engl. J. Med. 1999 341 : 1256 63.
18. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999 30 : 1082 7.
19. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 2004 9 : 679 93.
20. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999 30 : 770 4.
21. Lok AS. Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better? Gastroenterology 2000 119 : 263 6.
22. Besisik F, Karaca C, Akyuz F et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J. Hepatol. 2003 38 : 506 10.
23. Sun J, Wang Z, Ma S et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J. Med. Virol. 2005 75 : 391 8.
24. Kim HS, Han KH, Ahn SH et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir. Ther. 2005 10 : 441 9.
25. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001 34 : 617 24.
26. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999 30 : 567 72.